A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
HOME > BUSINESS
BUSINESS
- Otsuka, Lundbeck to Expand Collaboration, Copromote Abilify in US, Europe
March 11, 2013
- Ethical Drug Sales Up 4.8% in January: Crecon Report
March 11, 2013
- Astellas, UCB Japan Launch RA Treatment Cimzia
March 11, 2013
- NBI Calls for Proper Use of Prazaxa due to Unsatisfactory Compliance with Blue Letter
March 11, 2013
- Sandoz Will See Accelerated Growth of Japan Operations in 2013: Global Head
March 11, 2013
- Eisai to Reorganize Sales Force in Japan to Secure Aricept Market Share
March 8, 2013
- With Growing Competition from Foreign Drug Makers, Takeda Interested in Product Tie-ups: President Hasegawa
March 8, 2013
- Yakult Enters Biosimilars Business, Ties Up with UMN and API
March 7, 2013
- Novartis Withdraws Application for Glivec for PAH in Japan
March 7, 2013
- Ajinomoto to Acquire US Contract Biologic Manufacturer Althea
March 7, 2013
- Sawai's New Plant Starts Operation, Raising Annual Production Capacity to 8 Billion Tablets
March 6, 2013
- Nichi-Iko's New Factory Completed in Toyama, Production Capacity to Reach 7-8 Billion Tablets a Year
March 6, 2013
- DSP to Merge Its Clinical Development Functions with US Subsidiary’s
March 6, 2013
- Ranbaxy Resumes Production of Atorvastatin at US Plant
March 6, 2013
- 2 SGLT-2 Inhibitors to Be Filed for Approval without Concurrent-Use Restrictions
March 5, 2013
- Pfizer Positive about In-Licensing Other Firms’ Long-Listed Drugs: VP Matsumori
March 5, 2013
- 3-Drug H. pylori Eradication Therapies to Get Further Indication for Chronic Gastritis; Big Boost to PPI Market Expected
March 5, 2013
- Daiichi Sankyo to Set Up Biologics Oversight Function within R&D Division in Order to Enhance Biopharmaceutical Research Level
March 5, 2013
- Teva Pharma, Nippon Kayaku Receive Approval of Japan’s Second G-CSF Biosimilar
March 5, 2013
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
March 4, 2013
ページ
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…